Skip to main content

Table 6 Utility gain 6 and 12 months post-therapy initiation in anti-TNF responders and non-responders

From: Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

  Canada France UK Germany HK
Unadjusted (Mean ± SD)
 All users 
  Index 0.53 ± 0.08 0.53 ± 0.08 0.53 ± 0.07 0.54 ± 0.08 0.53 ± 0.07
  6 M after index visit 0.64 ± 0.13 0.63 ± 0.13 0.63 ± 0.13 0.65 ± 0.13 0.62 ± 0.13
  12 M after index visit 0.62 ± 0.12 0.61 ± 0.12 0.61 ± 0.11 0.63 ± 0.12 0.60 ± 0.11
 Responders
  Index 0.55 ± 0.09 0.55 ± 0.09 0.53 ± 0.08 0.55 ± 0.09 0.55 ± 0.08
  6 M after index visit 0.68 ± 0.12 0.67 ± 0.12 0.65 ± 0.12 0.69 ± 0.12 0.67 ± 0.11
  12 M after index visit 0.65 ± 0.12 0.64 ± 0.12 0.62 ± 0.10 0.66 ± 0.11 0.60 ± 0.10
 Non-responders
  Index 0.52 ± 0.06 0.52 ± 0.06 0.52 ± 0.07 0.52 ± 0.06 0.52 ± 0.07
  6 M after index visit 0.60 ± 0.13 0.59 ± 0.12 0.62 ± 0.14 0.61 ± 0.13 0.59 ± 0.13
  12 M after index visit 0.59 ± 0.12 0.58 ± 0.12 0.61 ± 0.12 0.60 ± 0.13 0.59 ± 0.11